Dr. John Cush RheumNow
2 years 10 months ago
Subtype of dermatomyositis is positive for Melanoma differentiation-associated protein 5 (MDA5) antibody. This poor prognosis subtype has distinctive rashes, rapidly progressive interstitial lung disease, lymphopenia &elevated ferritin levels https://t.co/FJjdO27cQQ https://t.co/gis2aWOLa7
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.
In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.
Dr. John Cush RheumNow
2 years 10 months ago
Early bird pricing has been extended! Register today!
https://t.co/BysC0RunUh https://t.co/4Ar0kHa4tt
Dr. John Cush RheumNow
2 years 10 months ago
Palmoplantar pustulosis (PPP) is difficult to treat; w/ few reports of JAKi efficacy. Now a report of 21 PPP pts given bimekizumab and 17 patients showed complete clearance in 1 to 4 months. SAPHO pts had complete clearance of skin & improved joint pain https://t.co/tYpHCxFOBI https://t.co/i4o3KnGlPY
Dr. John Cush RheumNow
2 years 10 months ago
UK Dermatology Registry of 13 699 Psoriasis pts on biologics (25K biologic exposures) found 1% risk of paradoxical eczema. Biologics included inhibitors of TNF, IL-17, IL12/23, IL-23. Lowest risk w/ IL-23i (0.56/100kPY), and higher w/ IL-17i (1.22) https://t.co/fOX6VGJQLk https://t.co/u1p1sidCte
Dr. John Cush RheumNow
2 years 10 months ago
Post-Menopausal Osteoporosis Review and Recommendations
A recent New England Journal review of post-menopausal osteoporosis (OP) provided updated information, strategies and a review of guidelines and clinical recommendations.
https://t.co/TkJjsX98Ww https://t.co/2Hi72GjEHM
Dr. John Cush RheumNow
2 years 10 months ago
ICYMI: The Heart of Lupus
Few people are aware of the EULAR recommendations1 for cardiovascular (CV) risk management in systemic lupus erythematosus (SLE) published in 2022. The recommendations had 4 overarching principles...
https://t.co/5I5eYNqHIu https://t.co/W6VzUFs6kN
Dr. John Cush RheumNow
2 years 10 months ago
Withdraw DMARDS after remission?
Considering withdrawing DMARDs after remission is on our minds. When patients inquire about tapering or stopping DMARDs while doing well, we often lack a clear-cut answer.
https://t.co/wqcCff7kjx https://t.co/vq9ee1dZNX
Dr. John Cush RheumNow
2 years 10 months ago
Calcineurin Inhibitors in Lupus Nephritis
Dr. Kathryn Dao discusses abstract 1509 with Dr. Gabriel Figueroa-Parra at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/1sjvCUyvD9 https://t.co/kocmtM1j6o
Dr. John Cush RheumNow
2 years 10 months ago
Pneumocystis Jiroveci Pneumonia (PJP) Risk
https://t.co/OTG9Ud1adu https://t.co/jIhdwws0Un
Dr. John Cush RheumNow
2 years 10 months ago
ICYMI: Are Rheumatologists doing Enough for Cervical Cancer?
https://t.co/afg5YL3RCN https://t.co/VRyKh6VgmS
Dr. John Cush RheumNow
2 years 10 months ago
Even low-dose, short-term steroid use increases the risk of serious CV events
Dr. Meral El Ramahi (Nashville, TN) reports on abstract 2430 presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/apgxXeVw1U https://t.co/zPiUCqtJlf
Dr. John Cush RheumNow
2 years 10 months ago
ILD Guidelines Indicators to Screen
Dr. Mike Putman reports from the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/PDE3eZ0Men https://t.co/7xlwrspq9U
